Comparison of Odonate Therapeutics Inc. (ODT) and Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX)

Odonate Therapeutics Inc. (NASDAQ:ODT) and Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Odonate Therapeutics Inc. N/A 0.00 88.96M -3.63 0.00
Eloxx Pharmaceuticals Inc. N/A 0.00 47.19M -1.64 0.00

Table 1 demonstrates Odonate Therapeutics Inc. and Eloxx Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Odonate Therapeutics Inc. 0.00% -55.9% -51.5%
Eloxx Pharmaceuticals Inc. 0.00% 0% 0%

Liquidity

Odonate Therapeutics Inc.’s Current Ratio and Quick Ratio are 7.7 and 7.7 respectively. The Current Ratio and Quick Ratio of its competitor Eloxx Pharmaceuticals Inc. are 11.1 and 11.1 respectively. Eloxx Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Odonate Therapeutics Inc.

Institutional & Insider Ownership

The shares of both Odonate Therapeutics Inc. and Eloxx Pharmaceuticals Inc. are owned by institutional investors at 94.9% and 54.2% respectively. Insiders owned roughly 2.4% of Odonate Therapeutics Inc.’s shares. Comparatively, insiders own roughly 0.3% of Eloxx Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Odonate Therapeutics Inc. 9.61% 2.6% 4.29% -17.99% -38.07% 20.74%
Eloxx Pharmaceuticals Inc. 3.99% 10.12% -16.74% -22.66% 82.67% 10.57%

For the past year Odonate Therapeutics Inc. was more bullish than Eloxx Pharmaceuticals Inc.

Summary

Eloxx Pharmaceuticals Inc. beats Odonate Therapeutics Inc. on 5 of the 6 factors.

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.